Welcome to our dedicated page for Elutia news (Ticker: $ELUT), a resource for investors and traders seeking the latest updates and insights on Elutia stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Elutia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Elutia's position in the market.
Rhea-AI Summary
Elutia Inc. (Nasdaq: ELUT) will report its first quarter 2024 financial results on May 9, 2024. The company specializes in drug-eluting biomatrix products. A conference call and webcast will be held on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
-
Rhea-AI Summary
Elutia Inc. (Nasdaq: ELUT) will present at the Planet MicroCap Showcase: VEGAS 2024 on May 1, 2024, featuring Dr. Randy Mills and Matt Ferguson. Elutia management will also engage in 1x1 investor meetings on May 2, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Elutia Inc. reports strong revenue growth in 2023, with sales increasing for SimpliDerm by 38% and CanGaroo by 3.4%. The company submitted a 510(k) premarket notification for CanGarooRM to the FDA, with positive interactions and no requests for additional data. Elutia closed the divestiture of the orthobiologics business, generating $14.6 million in cash proceeds. The company established a Strategic Advisory Committee for the commercial launch of CanGarooRM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.75%
Tags
News
Rhea-AI Summary
Elutia Inc. (ELUT) to report Q4 and full year 2023 financial results on March 7, 2024. Conference call and webcast scheduled. Investors can access the event through the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
-
Rhea-AI Summary
Elutia Inc. (Nasdaq: ELUT) has regained compliance with Nasdaq's market value of listed securities requirement and majority independent board requirement. The company now satisfies all applicable requirements for continued listing with Nasdaq, and its Class A common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol 'ELUT.' Elutia had a transformative year in 2023 with the divestiture of its orthopedics business and a successful capital raise. The CEO and leadership team are now focused on the commercial launch of their pioneering drug-eluting biomatrix, CanGarooRM®, with a favorable FDA decision expected in the first half of this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.67%
Tags
-
Rhea-AI Summary
Elutia Inc. (ELUT) has submitted a 510(k) premarket notification to the FDA for CanGarooRM, a next-generation drug-eluting biomatrix product tailored for use with cardiac implantable electronic devices. The company anticipates an approval decision in the first half of 2024 and is preparing for commercial launch. CanGarooRM is a bioenvelope made of a natural biomaterial that promotes a regenerative healing response and contains a slow-release formulation of antibiotics to reduce bacterial colonization. The product aims to address a $600 million market currently served by only one competitor, with potential expansion into other adjacent markets in the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
Rhea-AI Summary
Elutia Inc. (Nasdaq: ELUT) anticipates filing a 510(k) for transformational Drug-Eluting Biomatrix CanGarooRM in the fourth quarter of 2023. The company reported a 44% increase in SimpliDerm® net sales and an 11% growth in CanGaroo® net sales. Elutia divested its Orthobiologics business unit, secured private placement financing, and completed validation of an accelerated in-vitro elution assay for CanGarooRM. The company aims to capture a significant share of the $600 million CIED envelope market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.64%
Tags
-
News
Rhea-AI Summary
Elutia Inc. (Nasdaq: ELUT) announced the completion of the divestiture of its Orthobiologics business unit to Berkeley Biologics LLC, allowing the company to focus on its proprietary drug-eluting biomatrix platform. The transaction provides Elutia with up to $35 million in cash proceeds, including $15 million upfront and potential earnout payments of up to $20 million over five years. Combined with the previously announced private placement, the company potentially has access to over $60 million. Dr. Randy Mills, President and CEO, highlighted the company's focus on high-growth biomatrix product platforms, particularly the near-term blockbuster opportunity with CanGaroo®RM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.37%
Tags
-
Rhea-AI Summary
Elutia Inc. (Nasdaq: ELUT) will release its third quarter 2023 financial results after market close on November 13, 2023. The conference call and webcast will start at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Webcast and conference call details can be found on the Elutia website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
Rhea-AI Summary
Elutia's CEO to participate in panel at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
Elutia Inc.
Nasdaq:ELUT
ELUT Rankings
ELUT Stock Data
70.61M
7.25M
8.84%
69.93%
0.07%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
SILVER SPRING
About ELUT
aziyo was created by highcape partners and tissue banks international with the mission of restoring health and mobility to the greatest number of patients. our vision for aziyo is to impact healthcare as the premier partner in innovation of new solutions that realize the potential of regenerative medicine. honoring the gift from those who selfishly give the precious gift of donation to those who receive it, we are committed to honoring the lives of these brave individuals and their families everyday. whether you need a traditional bone graft, a processed osteobiologic, or a custom musculoskeletal tissue product, aziyo is committed to innovating new solutions that help fulfill the promise of regenerative medicine. at aziyo, we foster a collaborative environment where we deliver best-in-class solutions and operational excellence to our customers each and every day.